EPALINGES, Switzerland, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Mymetics Corporation (OTCBB:MYMX), a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that the company had been selected to present their ground breaking results obtained for their preventative HIV-1 vaccine.
The poster is titled "High Protection of Female Macaques from Repeated Intra-Vaginal Challenges with Low-dose of SHIV(SF162P3) upon Mucosal Vaccination with Gp41 subunits-Virosomes inducing Gp41-specific Mucosal Immune Responses". Results show high mucosal protection against repeated live SHIV vaginal challenges after vaccination with Mymetics' preventative HIV-1 vaccine candidate. The vaccinated group showed no detectable viremia while the placebo group became fully infected.
"We are very pleased to share our results with the scientific community attending to the world leading congress on AIDS vaccines," commented Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics Corp; "The results are very encouraging and we believe Mymetics' approach is opening the door to the development of preventative HIV-1 vaccine through mucosal defense mechanism."
About Mymetics
Swiss based, U.S. biotechnology company (OTCBB:MYMX), focused on the development of the next generation preventative vaccines for infectious diseases, with 5 vaccines in the pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. Mymetics core technology and know-how is based on the use of virosomes as a vaccine delivery platform combined with rationally designed antigens to induce protection acting on early transmission and infection events, including the mucosal immune response as a first barrier against the infection. Mymetics believes that this platform allows it to develop preventative vaccines for a broad range of diseases.
Mymetics will start the Phase I for HIV-1 vaccine. The Malaria vaccine is at the end of a Phase 1b trial with children in Tanzania, while the RSV and the HSV vaccine candidates are in pre-clinical phase. The Influenza virus is out-licensed to Solvay Pharmaceuticals. For further information, please visit: www.mymetics.com
The Mymetics Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5478
Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.